Revive Therapeutics (TSXV:RVV, OTCQB:RVVTF) announced a sponsored research agreement with the University of Wisconsin-Madison in order to check a drug delivery technology using cannabinoids for various diseases.
As quoted in the press release:

“We are very excited to advance a novel cannabinoid-focused drug delivery technology with the potential to safely and effectively treat, but not limited to, pain, inflammatory skin disorders, and liver diseases,” said Craig Leon, Chief Executive of Revive. “We are focused on continuing to build our cannabinoid-based product pipeline and our expansion in cannabinoid-based drug delivery reinforces our commitment to this strategy. Our research relationship with the University of Wisconsin-Madison builds upon our efforts to lead the way in providing novel cannabinoid-based therapies for serious and unmet medical needs.”
The research program will be led by Jess D. Reed, Ph.D., Professor of Animal Sciences at the University of Wisconsin-Madison. Under the agreement, Dr. Reed and his research team will evaluate the role and potential use of a chitosan-tannins based formula for the delivery of cannabinoids. The research will be based on Dr. Reed’s patented technology in the use of tannin-chitosan composites for therapeutic biomaterials.
“I am very excited about the potential and the initiation of the development of a novel ground-breaking cannabinoid-focused drug delivery technology,” said Dr. Jess Reed, Professor of Animal Sciences at the University of Wisconsin-Madison. “The opportunities of the drug delivery technology and cannabinoids are plentiful and I look forward to validating the true potential of the drug delivery technology in allowing novel ways to deliver cannabinoids for various diseases.”


Click here to read the full press release.

Source: www.marketwired.com

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less